Departments of Emergency Medicine, Obstetrics and Gynecology, and Clinical Investigation, Naval Medical Center, San Diego, California; and the Department of Emergency Medicine, Naval Medical Center, Portsmouth, Virginia.
Obstet Gynecol. 2014 Oct;124(4):735-742. doi: 10.1097/AOG.0000000000000479.
To evaluate whether ondansetron or the combination of doxylamine and pyridoxine was superior for the treatment of nausea and vomiting of pregnancy.
This was a double-blind, randomized, controlled trial in which women with nausea and vomiting of pregnancy were assigned to 4 mg of ondansetron plus a placebo tablet or 25 mg pyridoxine plus 12.5 mg of doxylamine for 5 days. The primary outcome was an improvement in nausea as reported on a 100-mm visual analog scale (VAS). Secondary outcomes were a reduction in vomiting on the VAS and the proportion of patients reporting sedation or constipation while using either study regimen.
Thirty-six women (18 in each group) were randomized to either ondansetron or pyridoxine and doxylamine, of whom 13 (72%) and 17 (94%) completed follow-up, respectively. There were no differences among the groups with regard to demographic characteristics or baseline nausea. Patients randomized to ondansetron were more likely to have an improvement in their baseline nausea as compared with those using pyridoxine and doxylamine over the course of 5 days of treatment (median VAS score decreased 51 mm [interquartile range 37-64] compared with 20 mm [8-51]; P=.019). Furthermore, women using ondansetron reported less vomiting (median VAS decreased 41 [interquartile range 17-57] compared with 17 [-4 to 38]; P=.049). There was no significant difference between the groups regarding sedation or constipation.
Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy.
ClinicalTrials.gov, www.clinicaltrials.gov, NCT01668069.
: I.
评估昂丹司琼或多西拉敏与吡哆醇联合应用在治疗妊娠恶心呕吐方面是否更具优势。
这是一项双盲、随机、对照试验,将妊娠恶心呕吐的女性患者随机分为两组,一组给予昂丹司琼 4mg 联合安慰剂片,另一组给予 25mg 吡哆醇联合 12.5mg 多西拉敏,连续用药 5 天。主要结局是根据 100mm 视觉模拟量表(VAS)评估的恶心改善情况。次要结局是 VAS 评估的呕吐减少情况以及报告使用任何一种研究方案时出现镇静或便秘的患者比例。
36 名女性(每组 18 名)被随机分配至昂丹司琼组或吡哆醇与多西拉敏组,其中分别有 13 名(72%)和 17 名(94%)患者完成了随访。两组患者在人口统计学特征或基线恶心程度方面无差异。与使用吡哆醇与多西拉敏的患者相比,接受昂丹司琼治疗的患者在 5 天治疗期间其基线恶心程度更可能得到改善(VAS 评分中位数降低 51mm[四分位距 37-64],而降低 20mm[8-51];P=.019)。此外,使用昂丹司琼的女性报告的呕吐更少(VAS 评分中位数降低 41[17-57],而降低 17[-4-38];P=.049)。两组在镇静或便秘方面无显著差异。
我们的研究表明,昂丹司琼在治疗妊娠恶心和呕吐方面优于吡哆醇与多西拉敏联合应用。
ClinicalTrials.gov,www.clinicaltrials.gov,NCT01668069。
I 级。